The estimated Net Worth of Susan Molineaux is at least $2.21 Milion dollars as of 1 May 2023. Susan Molineaux owns over 35,000 units of Calithera Biosciences Inc stock worth over $1,750 and over the last 12 years he sold CALA stock worth over $0. In addition, he makes $2,209,840 as President, Chief Executive Officer, Co-Founder a Director at Calithera Biosciences Inc.
Susan has made over 10 trades of the Calithera Biosciences Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 35,000 units of CALA stock worth $38,500 on 1 May 2023.
The largest trade he's ever made was buying 100,000 units of Calithera Biosciences Inc stock on 10 November 2021 worth over $85,000. On average, Susan trades about 5,771 units every 40 days since 2012. As of 1 May 2023 he still owns at least 35,000 units of Calithera Biosciences Inc stock.
You can see the complete history of Susan Molineaux stock trades at the bottom of the page.
Dr. Susan M. Molineaux Ph.D. serves as President, Chief Executive Officer, Co-Founder, Director of the Company. Dr. Molineaux has served as our President, Chief Executive Officer and as a member of our board of directors since she co-founded Calithera in March 2010. Dr. Molineaux co-founded Proteolix, Inc., a biopharmaceutical company, where she served as Chief Scientific Officer from 2003 to 2005, Chief Executive Officer from January 2006 to January 2009 and again as Chief Scientific Officer from February 2009 until Proteolix’s acquisition by Onyx Pharmaceuticals, Inc. in November 2009. From 2000 to 2003, Dr. Molineaux served as Vice President of Biology at Rigel Pharmaceuticals, Inc., a drug development company. From 1999 to 2000, she served as Vice President of Biology at Praelux, Inc., a biopharmaceutical company, and from 1994 through 1999, she served as Vice President of Drug Development at Praecis Pharmaceuticals, Inc., a biopharmaceutical company. From 1989 until 1994, she was a scientist in the Immunology group at Merck & Co. Dr. Molineaux currently serves as a member of the board of directors of Geron Corporation, Theravance Biopharma, Inc. and Smith College, and is a Scientific Advisor for Lightstone Ventures. Dr. Molineaux holds a B.S. in Biology from Smith College and a Ph.D. in Molecular Biology from Johns Hopkins University, and completed a postdoctoral fellowship at Columbia University.
As the President, Chief Executive Officer, Co-Founder a Director of Calithera Biosciences Inc, the total compensation of Susan Molineaux at Calithera Biosciences Inc is $2,209,840. There are no executives at Calithera Biosciences Inc getting paid more.
Susan Molineaux is 66, he's been the President, Chief Executive Officer, Co-Founder a Director of Calithera Biosciences Inc since 2010. There are 3 older and 18 younger executives at Calithera Biosciences Inc. The oldest executive at Calithera Biosciences Inc is H. Ward Wolff, 71, who is the Independent Director.
Susan's mailing address filed with the SEC is C/O REPARE THERAPEUTICS INC., , ST-LAURENT, A8, H4S 1Z9.
Over the last 10 years, insiders at Calithera Biosciences Inc have traded over $23,150,153 worth of Calithera Biosciences Inc stock and bought 7,859,025 units worth $49,155,939 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Capital Partners Gp, L.L.C.... a Deepika Pakianathan. On average, Calithera Biosciences Inc executives and independent directors trade stock every 43 days with the average trade being worth of $8,053. The most recent stock trade was executed by Deepika Pakianathan on 27 January 2023, trading 121,333 units of CALA stock currently worth $47,320.
calithera is focused on discovering and developing first-in-class small molecule drugs that slow tumor growth through controlling key metabolic pathways in the tumor and immune cells. tumor metabolism and tumor immunology are promising new interrelated fields for cancer drug discovery. recent clinical successes have demonstrated the potential to slow abnormal cell growth and create fundamentally new therapies for cancer patients. our investigational onco-metabolism medicines take advantage of the different metabolic requirements of tumor cells and cancer-fighting immune cells. calithera’s discovery and development efforts are focused on solid tumors for which new treatments are urgently needed. we are currently developing our lead candidate in phase 2 trials in patients with renal cell carcinoma, triple negative breast cancer. targeting cancer, differently. our onco-metabolism approach brings an enhanced perspective to cancer.
Calithera Biosciences Inc executives and other stock owners filed with the SEC include: